OncoTalks | Oncology Insights at Your Fingertips

OncoTalks is the podcast for community oncology providers and clinicians who want to stay on top of new treatments and the latest advancements in oncology. Join Ontada Learn and community oncologists from The US Oncology Network as they explore oncology with a focus on the latest breakthroughs in cancer care. Expect concise, impactful discussions with practical clinical insights tailored for the real-world community oncology setting. Additionally, don’t miss OncoTalks Case Journeys , where experts deep dive into oncology patient cases and treatment journeys. Join as they conduct comprehensive case reviews, explore key learnings, and discuss the latest research and advances related to each case. Tune into OncoTalks and start unlocking pathways to better patient care today!

OncoTalks | Oncology Insights at Your Fingertips is a education podcast hosted by Unknown Host, with 41 episodes on record and a Required Pod Score of 80.

Unknown Host hosts OncoTalks | Oncology Insights at Your Fingertips, a education show with 41 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #49

  Long-Term BTKi Success: Adherence, Dosing, and Patient Support in CLL

  Sep 25, 202616 min

  Adherence starts long before the first missed dose. In this episode, Dr. Brad Christensen shares real-world insights on helping patients with chronic lymphocytic leukemia (CLL) stay on BTK inhibitor therapy over the long term. Topics include individualized treatment selection, the role of dosing flexibility in real-world practice, and proactive adverse event management. Dr. Christensen also highlights the importance of frequent early follow-up, patient education, and home monitoring to support treatment continuity and optimize outcomes throughout the patient journey. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

  ListenShow Notes
• 

  Episode #48

  Micro-Series | Part 4 | Optimizing Long-Term TKI Therapy in Resistant CML

  Sep 4, 20264 min

  In the final installment, Dr. Luke Fletcher shares strategies for managing resistant chronic myeloid leukemia (CML), including adverse event monitoring, supportive care, and response-based dose optimization to improve long-term treatment success. This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL and CML: A Practical Guide to Treatment, Monitoring, and Resistance. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

  ListenShow Notes
• 

  Episode #47

  Micro-Series | Part 3 | Managing Resistance in CML: When and Why to Test for BCR-ABL1 Mutations

  Sep 4, 20264 min

  Dr. Luke Fletcher discusses mutation testing in chronic myeloid leukemia (CML), including when to test, how results influence treatment decisions, and the clinical significance of mutations such as T315I. This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL and CML: A Practical Guide to Treatment, Monitoring, and Resistance. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

  ListenShow Notes
• 

  Episode #46

  Micro-Series | Part 2 | Measuring Molecular Response in Ph+ ALL

  Aug 28, 20264 min

  Dr. Luke Fletcher examines the growing role of measurable residual disease (MRD) and molecular response in treatment monitoring, and the impact of tyrosine kinase inhibitor (TKI) selection on achieving deep and durable responses for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL and CML: A Practical Guide to Treatment, Monitoring, and Resistance. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

  ListenShow Notes
• 

  Episode #45

  Micro-Series | Part 1 | TKIs in Frontline Ph+ ALL Treatment

  Aug 28, 20264 min

  Dr. Luke Fletcher reviews the evolving treatment approach for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), highlighting how tyrosine kinase inhibitors (TKIs) are integrated throughout induction, consolidation, and maintenance therapy to support long-term disease control. This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL and CML: A Practical Guide to Treatment, Monitoring, and Resistance. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

  ListenShow Notes

Recent guests on OncoTalks | Oncology Insights at Your Fingertips. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.